Although statistical significance was not reached, neoadjuvant oxaliplatin has been shown to upregulate Src pathway activation, and any detriment in overall survival caused by activation of these signal transduction pathways in generating chemoresistance may be confounded by the survival benefit of neoadjuvant oxaliplatin in the treatment of metastatic colorectal cancer [25]. Here, SRC is linked to metastatic colorectal cancer.